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Abstract
Background: Cardiovascular magnetic resonance (CMR) is considered an attractive alternative for guiding
transarterial aortic valve implantation (TAVI) featuring unlimited scan plane orientation and unsurpassed soft-tissue
contrast with simultaneous device visualization. We sought to evaluate the CMR characteristics of both currently
commercially available transcatheter heart valves (Edwards SAPIEN™, Medtronic CoreValve®) including their
dedicated delivery devices and of a custom-built, CMR-compatible delivery device for the Medtronic CoreValve®
prosthesis as an initial step towards real-time CMR-guided TAVI.
Methods: The devices were systematically examined in phantom models on a 1.5-Tesla scanner using high-
resolution T1-weighted 3D FLASH, real-time TrueFISP and flow-sensitive phase-contrast sequences. Images were
analyzed for device visualization quality, device-related susceptibility artifacts, and radiofrequency signal shielding.
Results: CMR revealed major susceptibility artifacts for the two commercial delivery devices caused by
considerable metal braiding and precluding in vivo application. The stainless steel-based Edwards SAPIEN™
prosthesis was also regarded not suitable for CMR-guided TAVI due to susceptibility artifacts exceeding the valve’s
dimensions and hindering an exact placement. In contrast, the nitinol-based Medtronic CoreValve® prosthesis was
excellently visualized with delineation even of small details and, thus, regarded suitable for CMR-guided TAVI,
particularly since reengineering of its delivery device toward CMR-compatibility resulted in artifact elimination and
excellent visualization during catheter movement and valve deployment on real-time TrueFISP imaging. Reliable
flow measurements could be performed for both stent-valves after deployment using phase-contrast sequences.
Conclusions: The present study shows that the Medtronic CoreValve® prosthesis is potentially suited for real-time
CMR-guided placement in vivo after suggested design modifications of the delivery system.
Background
Transcatheter, transarterial aortic valve implantation
(TAVI) is rapidly emerging as a promising new treatment
option for patients with severe symptomatic aortic valve
stenosis who are considered at high or prohibitive surgi-
cal risk [1,2]. Safe navigation of the valve delivery devices
through the vasculature and precise placement of the
stent-valve prostheses within the native aortic valve
annulus are the challenging key steps of the procedure,
which is currently performed under X-ray fluoroscopic
and angiographic guidance. X-ray fluoroscopy and angio-
graphy, however, entail several shortcomings beyond the
inherent harmful effects of radiation exposure which may
be overcome by real-time cardiovascular magnetic reso-
nance (CMR) guidance, offering real-time image acquisi-
tion with unrestricted scan plane orientation and
superior, detailed soft-tissue contrast with simultaneous
visualization of the interventional device [3,4] as
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animal studies, including percutaneous transluminal
angioplasties [5], selective embolization procedures [6],
placement of atrial septal closure devices [7], peripheral
[8,9] as well as coronary stent placement [10], stenting of
aortic coarctation [11], and aortic stent-graft placement
[12].
In the setting of TAVI, CMR guidance offers an
improved intraprocedural guidance for navigation of the
large-diameter catheters through the vasculature. More-
over, CMR appears to be particularly advantageous over
X-ray fluoroscopy and angiography during valve implan-
tation since it permits precise, real-time orientation for
axial positioning and deployment of the prosthesis with-
out the need for contrast media, not even gadolinium.
This may also help to reduce the total amount of
nephrotoxic contrast media potentially causing acute
kidney injury which has been shown to increase the risk
of postoperative mortality in the elderly TAVI patient
population [13]. Although transesoephageal echocardio-
graphy including real-time 3D imaging is used as a help-
ful adjunct imaging modality [14], this technique has not
eliminated the need for fluoroscopy and angiography.
In addition to an improved procedural guidance, CMR
may also be useful for preinterventional diagnostic eva-
luation of the aortic valve aortic valve [15,16] and the
vascular aortic anatomy for interventional planning [17]
as well as for immediate evaluation of the result [18-20].
Furthermore, TAVI appears particularly attractive for a
CMR-guided approach, since device delivery is per-
formed through large-diameter vessels, i.e. the femoral
or subclavian artery, and the delivery devices come with
a rather large instrument caliber of 18 to 24 French
outer diameter. Hence, TAVI is amenable to passive
catheter tracking and may be performed without the
need for additional device mod i f i c a t i o n sa sn e e d e df o r
active CMR visualization approaches [3,4].
In the present study, the CMR characteristics of the
two currently commercially available transcatheter heart
valves with their dedicated transfemoral delivery devices
(Edwards SAPIEN™, Edwards Lifesciences Inc., Irvine,
CA, USA; Medtronic CoreValve®, Medtronic, Inc., Min-
neapolis, MN, USA) and of a custom-built delivery
device for the Medtronic CoreValve® bioprosthesis with
design modifications targeted toward improved CMR
safety and CMR compatibility have been systematically
investigated in phantom experiments. This study is
intended to serve as an initial step toward real-time
CMR-guided TAVI in vivo.
Methods
TAVI Devices
The two currently commercially available transcatheter
heart valves - the balloon-expandable Edwards SAPIEN™
and the self-expandable Medtronic CoreValve® bio-
prosthesis - and their dedicated transfemoral delivery
devices were examined (Figure 1). Additionally, a cus-
tom-built, modified CMR-compatible delivery device for
the Medtronic CoreValve® bioprosthesis was designed
and evaluated (Figure 2).
1. Edwards SAPIEN™-Prosthesis and Delivery Device
The balloon-expandable Edwards SAPIEN™ prosthesis is a
tubular, slotted, stainless steel stent with an attached uni-
directional trileaflet bovine pericardial tissue valve and a
fabric sealing cuff. Prior to implantation, the biosprosthesis
is mounted and crimped onto a balloon catheter (Z-MED
II, NuMED, Inc., Hopkinton, NY, USA) using a specially
designed crimping device. When the stent-valve is cor-
rectly positioned within the native aortic valve annulus it
is deployed by balloon inflation under partial cardiac arrest
induced by rapid right ventricular pacing.
The dedicated delivery device of the Edwards
SAPIEN™ prosthesis consists of a large-diameter over-
the-wire guiding catheter of 22 or 24 French (for the 23
mm and the 26 mm stent-valve, respectively) which is
used for advancing the prosthesis through the vascula-
ture and tracking it through the aortic arch (RetroFlex,
Edwards Lifesciences Inc., Irvine, CA, USA), and the
aforementioned balloon catheter which protrudes dis-
tally from the guiding catheter. The guiding catheter
shaft has a polytetrafluoroethylene-lined, stainless steel
braided multidurometer PEBAX™/VESTAMID™ con-
struction ensuring enough rigidity for pushing and tor-
quing. An incorporated softer mid-distal section made
of soft durometer PEBAX™ gives the catheter greater
flexibility for propagation through the aortic arch and
allows steerable deflection from 0 to 120 degrees. This
is achieved by a laser-welded stainless steel pull wire
which is connected to a slide nut and to guides that
direct the pull wire and, thereby, the central lumen to
the proper path when the rotational grip at the handle
of the guiding catheter is operated (Figure 1).
2. Medtronic CoreValve® Bioprosthesis and Delivery Device
The self-expandable Medtronic CoreValve® bioprosthesis
is composed of a tri-level nitinol stent frame with an
integrated uni-directional trileaflet porcine pericardial
tissue valve. The inflow portion of the stent-valve has a
high radial stiffness in order to anchor the stent within
the calcified, native aortic valve leaflets; the middle por-
tion is waisted, thereby maintaining coronary perfusion;
and the outflow portion implants itself in the ascending
aorta to orient the prosthesis parallel to the blood flow.
The delivery system is an over-the-wire catheter with a
composite 12 French polytetrafluoroethylene, metal braided,
Aesno nylon 12 shaft and an 18 French RILSAN®/PEBAX®
distal end (“capsule”) sheathing the crimped prosthesis,
which can be released stepwise with nearly continuous pre-
servation of transaortic blood flow. Release of the prosthesis
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nate, acrylonitrile-butadiene-styrene, acetal handle which
causes antagonist movement of the sheath and an inner
polyetheretherketone, stainless steel hypotube element,
thereby progressively unsheathing and finally releasing the
crimped stent-valve.
Engineering data and initial screening of both com-
mercially available delivery systems (Edwards and Med-
tronic) for metallic components revealed reinforcement
of the devices by ferromagnetic metal braiding, as well
as use of ferromagnetic markers which may affect CMR
compatibility and CMR safety. Both delivery devices
thus revealed significant ferromagnetic attraction when
brought near the magnet bore and showed ferromag-
netic metal artifacts exceeding the device diameters. For
this study, it was thus decided to develop and investigate
am o d i f i e dv e r s i o no ft h ed e l i v e r yd e v i c ef o rt h eM e d -
tronic CoreValve® bioprosthesis.
3. Modified Delivery Device for the Medtronic CoreValve®
Bioprosthesis
Design modifications of the delivery device for the self-
expandable, nitinol-based Medtronic CoreValve®
bioprosthesis towards improved CMR safety and compat-
ibility was performed with the help of Evasc Medical Sys-
tems (Evasc Medical Systems, Vancouver, BC, Canada). For
this purpose, the delivery catheter was designed completely
without the use of metallic components such as marker
bands or reinforcing wire braids. The modified device was
constructed with a polytetrafluoroethylene outer shaft and
a nylon stabilizer tube (Figure 2). The deployment of the
stent-valve is achieved by holding the catheter’s stabilizer
handle in a fixed position while sliding the deployment
handle, which is connected to the outer shaft, towards the
stabilizer handle. The stabilizer maintains the position of
the crimped stent valve while the outer shaft is retracted
allowing stepwise expansion of the prosthesis in the desired
location. This deployment method is common to many
delivery catheters for self-expanding devices.
The design modification resulted in a slight but practi-
cally negligible increase in the crossing profile from 18
to 20 French - when compared to the original Medtro-
nic CoreValve® delivery catheter - in order to contain all
relevant tubing and to match the relevant mechanical
properties of the original, metal reinforced device, speci-
fically flexibility and rigidity which are required for pro-
pagation of the device through the ilio-femoral vessels,
the aorta and the aortic arch. Although flexibility and
rigidity were not quantitatively bench-tested, the modi-
fied device showed similar properties to the original
device when manually manipulated (Figure 2).
Figure 1 TAVI Devices. Photograph of the two commercially available devices for transarterial aortic valve implantation: the balloon-
expandable, stainless steel-based Edwards SAPIEN™ stent-valve and its dedicated transfemoral RetroFlex delivery system (top) as well as the self-
expandable, nitinol-based Medtronic CoreValve® bioprosthesis and its original delivery catheter (bottom).
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Scanning was performed on a 1.5-Tesla whole-body
CMR scanner (Magnetom Avanto, Siemens Healthcare
Sector, Erlangen, Germany) equipped with gradients
capable of a maximum amplitude of 40 mT/m and a
slew rate of 200 T/m s
-1. The stent-valves and their
delivery systems were placed in a phantom containing
water and gadolinium contrast agent (Omniscan,
Amersham Health, Princeton, NJ, USA) at a concentra-
tion of 1:40. The phantom consisted of a 1-m-long, 10-
cm-diameter Plexiglas tube with a central hole for linear
catheter manipulation over a taut 0.8-mm-diameter
Nylon cord simulating a guide-wire. At the proximal
end, the phantom tube was equipped with a 30 French
introducer sheath sealed by a silicone membrane to
allow for introduction and rapid exchange of different
vascular instruments. The phantom was designed to
enable CMR assessment of the delivery device and the
stent-valve artifact properties in static conditions as well
as during manual catheter advancement and subsequent
valve deployment utilizing real-time CMR. The phantom
was placed longitudinal to the axis of the main magnetic
field on top of a multichannel spine phased-array RF
coil with three clusters of coil elements activated for sig-
nal reception (Tim Technology, Siemens Healthcare
Sector, Erlangen, Germany). A two-element BodyFlex
phased-array RF coil (Tim Technology, Siemens Health-
care Sector, Erlangen, Germany) was placed on top of
the phantom for signal reception (Figure 3). This setting
has been previously used by our group to evaluate
Figure 2 Modified Delivery Device for the Medtronic CoreValve(R) prosthesis. a. Photograph of the modified delivery device (top) and
schematic drawing with labeling of the relevant parts (bottom). b. Photograph of the original, reinforced delivery device for the Medtronic
CoreValve® bioprosthesis and the custom-built, CMR-compatible device, displaying similar flexibility and rigidity under manually bending.
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placement [21] prior to in vivo application [12].
High-Resolution CMR
In an initial experiment, the expanded stent-valves and
the delivery devices were separately imaged while sus-
pended freely in the water bath phantom in order to
determine device-related imaging artifacts. Imaging was
performed using high-resolution T1-weighted 3D fast
low-angle shot (FLASH) imaging to cover the whole
extent of the devices (imaging parameters: repetition
time (TR) 4.2 ms, echo time (TE) 1.7 ms, flip angle 40°,
field-of-view (FOV) 220 × 90 mm
2, matrix 512 × 204,
104 slices, bandwidth 510 Hz/pixel, acquisition time
(TA) 3:09 minutes). The acquired spatial resolution
resulted in 0.4 × 0.4 × 0.8 mm
3 voxel size.
Real-time CMR
The delivery devices were subsequently examined under
dynamic conditions with 2D real-time fast imaging with
steady-state precession (rt-TrueFISP) sequences using a
Cartesian reconstruction scheme (imaging parameters:
TR 3.2 ms, TE 1.6 ms, flip angle 60°, FOV 300 × 150
mm
2, matrix 256 × 128, bandwidth 1220 Hz/pixel, TA
0.41 seconds/image), both with and without the
mounted stent-valves. The frequency-encoding direction
was chosen parallel to the longitudinal direction of the
devices and of the phantom; thus, it was also parallel to
the direction of the main magnetic field. Images were
displayed inside the CMR scanner room using an inter-
ventional in-room console with a RF-shielded screen
(Siemens Healthcare Sector, Erlangen, Germany) to pro-
vide real-time visualization for the operator during sub-
sequent device movement and valve deployment.
The delivery devices were advanced at approximately
2 cm/s under real-time TrueFISP imaging. After
approximately 20 cm longitudinal device movement, the
devices were stopped and the release mechanism
applied. In the case of the balloon-expandable stent-
valve, the balloon catheter was advanced separately
without the guiding catheter to evaluate balloon infla-
tion and deflation. Subsequently, TrueFISP imaging was
used for precise real-time monitoring of valve deploy-
ment in a plastic tube, which was added to the phantom
model to simulate the aortic annulus and ascending
aorta. Since the guiding catheter of the balloon-expand-
able Edwards SAPIEN™ stent-valve revealed severe sus-
ceptibility artifacts, the over-the-wire balloon catheter
was also used without the guiding catheter to deploy the
balloon-mounted valve.
After deployment within the plastic tube, the bio-
prostheses were again examined with high-resolution
T1-weighted 3D fast low-angle shot (FLASH) sequences
(see parameters above) to evaluate correct positioning.
Flow Measurements
Finally, measurements of flow dynamics were performed
in a flow phantom model using flow-sensitive phase-
contrast (PC) sequences. The custom-built flow phan-
tom consisted of a system of plastic tubes contained in
a water-filled barrel and was placed longitudinally along
the axis of the main magnetic field as described above
for the Plexiglas phantom. The plastic tube system was
comprised of three different tubes, namely a cone-
shaped inflow part, a connecting piece, and an outflow
part with a proximal neck of 23 mm inner diameter to
accommodate the stent-valves.
A flow pump consisting of a CMR-compatible piston
pump capable of flow rates between 0.1 and 35 ml/s
(CompuFlow 1000 MR, Shelley Medical Imaging Tech-
nologies, Toronto, Ontario, Canada) and a control unit
with proprietary software (SimuFlow III, Shelley Medical
Imaging Technologies, Toronto, Ontario, Canada) was
used to simulate transaortic in vivo blood flow. Thereto,
a physiological, pre-programmed, pulsatile waveform
was reshaped with the peak flow rate set to the
Figure 3 Experimental setup. The TAVI devices were contained in
a Plexiglas phantom consisting of a 1-m-long, 10-cm-diameter tube
that was placed longitudinal to the main magnetic field of the MRI
scanner on top of a spine and below a body phased-array RF coil
for signal reception. Four water-filled bottles were placed beside the
phantom for RF transmit body coil loading.
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with reversed flow direction (peak reverse flow rate: 15
ml/s) for inducing closure of the valve leaflets. A dedi-
cated ECG trigger output of the flow pump allowed for
the compulsory ECG gating of the PC CMR imaging
sequences.
PC cine acquisitions were obtained in planes orthogo-
nal to the direction of flow approximately 2 cm down-
stream and 2 cm upstream from the prosthesis. An
ECG-triggered through-plane phase-contrast sequence
(2D FLASH) was used (imaging parameters: TR 62 ms,
TE 3.5 ms, flip angle 30°, FOV 320 × 220 mm
2,m a t r i x
192 × 132, bandwidth 555 Hz/pixel, TA 1:52 minutes).
The velocity-encoded value (VENC) of the PC
sequence was set to 100 cm/s for these flow phantom
experiments. By manually drawing regions of interest
over the appropriate areas, PC flow curves were
acquired and integrated over time using vendor-pro-
vided software (Argus, Siemens Healthcare Sector,
Erlangen, Germany).
Data Analysis
Image quality was evaluated with respect to static visua-
lization of the stent-valves and the delivery devices and
with respect to dynamic, real-time visualization during
longitudinal motion and during valve deployment.
Image quality assessment was performed in consensus
by a radiologist and a physicist using the following grad-
ing: severe artifacts with poor visualization (1 point),
minor artifacts allowing fair visualization (2 points), and
excellent visualization with delineation of device details
(3 points).
Assessment of RF signal shielding of the inside of the
expanded stent-valves due to RF signal caging was
expressed as percentage signal loss within the valve
l u m e no nt h eT 1-weighted 3D FLASH images with
respect to the undisturbed signal in the water/gadoli-
nium solution outside of the stent-valve [22]. For this
purpose, signal intensity was measured at regions of
interest (ROI) within the stent-valve as well as outside
in coronal and axial orientations. To account for inher-
ent spatial signal variations due to different locations of
the regions of interest relative to the position of the sur-
face coils, three measurements were taken and averaged.
In addition, these T1-weighted 3D FLASH sequences
were evaluated for regional signal enhancements due to
RF resonance effects.
Results
High-Resolution CMR
High-resolution T1-weighted 3D FLASH imaging pro-
vided fair visualization of the tubular, slotted, stainless
steel-based balloon-expandable Edwards SAPIEN™ stent-
valve with only minor susceptibility artifacts. However,
these artifacts rendered the stent slightly larger than its
true dimensions, which may be problematic for proce-
dural guidance of TAVI in vivo (Figure 4). In addition,
the associated delivery catheter revealed major suscept-
ibility artifacts caused by considerable metal braiding,
detrimentally affecting detailed visualization and raising
safety concerns in terms of RF-induced device heating
(Figure 5a). Moreover, the delivery device also exerted
significant ferromagnetic attraction forces in the vicinity
of the CMR scanner, which may potentially impose a
risk of deflection and migration during TAVI, thus pre-
cluding in vivo application. However, the balloon cathe-
ter showed excellent visualization without any artifacts
when examined separately.
The nitinol-based self-expandable Medtronic Core-
Valve® prosthesis was excellently visualized, with deli-
neation even of small device details. Its struts and
nodes, establishing the repeating diamond cell config-
uration of the stent frame, could be depicted in great
detail. Even the two eyelets at the outflow tract portion
of the stent were clearly displayed (Figure 4). While the
distal end of the delivery catheter into which the stent-
valve is loaded was excellently visualized without any
artifacts, the catheter shaft showed severe ferromagnetic
susceptibility artifacts similar to the delivery catheter of
the Edwards SAPIEN™ prosthesis. Nevertheless, the cir-
cumscribed but easily perceived susceptibility artifacts of
the crimped nitinol stent still enabled a clear determina-
tion of its position within the distal portion of the deliv-
ery device, this being an essential prerequisite for
precise valve positioning during deployment (Figure 5b).
Overcoming the limitations of the commercial device,
the modified delivery catheter for the Medtronic Core-
Valve® prosthesis, which was designed completely with-
out reinforcement of the shaft by metal braiding, was
rendered free of any susceptibility artifacts and provided
excellent visualization with great detail and clear deter-
mination of the loaded stent-valve position (Figure 5c).
Real-Time CMR
The rt-TrueFISP sequence allowed for time-resolved
display of device motion within the phantom model at a
real-time frame rate of 2.5 images/second without any
detectable image reconstruction delay or movement arti-
facts, thus ensuring a sufficiently high temporal resolu-
tion for visualization of the dynamic processes of
catheter movement and subsequent valve deployment.
The guiding catheter of the Edwards SAPEN™ stent-
valve showed severe susceptibility artifacts exceeding the
geometrical constraints of the instrument and rendering
the displayed instrument diameter larger than its real
diameter. Major image distortion was observed in the
device vicinity, as already anticipated from high-resolu-
tion imaging, precluding any precise visualization and
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Page 6 of 14Figure 4 High-Resolution CMR - Stent-Valves. Photograph (left
side) of the Edwards SAPIEN™ (top) and the Medtronic CoreValve®
bioprostheses (bottom) with corresponding single coronal slices
from high-resolution T1-weigthed 3D FLASH sequences (right side).
While RF signal attenuation within the stent was similar for both
stent-valves, the Medtronic CoreValve® prosthesis could be depicted
in greater detail, even showing the eyelets (arrows) at the outflow
tract of the stent. Such a subtle and constrained artifact may
potentially be used to indicate orientation before and during valve
deployment. This may become relevant in the future of TAVI when
rotational orientation with regards to the coronary ostia has to be
respected with new devices such as the self-expandable, Acurate
RP™ porcine bioprosthesis (Symetis S.A., Lausanne, Switzerland).
Likewise, the Edwards SAPIEN™ prosthesis exhibits a somewhat
inhomogeneous artifact (arrows) caused by the joint insertion of
two adjacent leaflets at the stent-frame, thereby resembling one of
the three commissures.
Figure 5 High-Resolution CMR - Delivery Devices. a. Left:
Photograph of the 24 French RetroFlex delivery catheter for the
Edwards SAPIEN™ stent-valve and visualization with high-resolution
T1-weighted 3D FLASH imaging revealing major susceptibility
artifacts caused by metal braiding. Middle: Photograph of the balloon
catheter on which the stent-valve is crimped for deployment and
corresponding CMR image in static position using real-time TrueFISP
imaging. The balloon catheter could be well visualized without any
disturbing artifacts. Right: Photograph of the inflated balloon
catheter, which could be depicted artifact-free with dark contrast
with real-time TrueFISP imaging. b. Left: Photograph of the
commercially available delivery catheter of the Medtronic CoreValve®
prosthesis and visualization with high-resolution T1-weighted 3D
FLASH imaging showing severe ferromagnetic artifacts of the
catheter shaft but good image quality without disturbing artifacts of
the metal-free distal part. Middle: Photograph of the delivery catheter
in the release position and corresponding high-resolution CMR
image displaying the distal portion of the delivery catheter in great
detail. Right: Photograph and corresponding high-resolution CMR
image of the loaded delivery catheter. The crimped nitinol stent-
valve can be made out easily by its circumscribed ferromagnetic
artifacts. c. Left: Photograph of the modified delivery catheter for the
Medtronic CoreValve® prosthesis and detailed visualization with high-
resolution T1-weighted 3D FLASH imaging in excellent quality
without any disturbing artifacts. Middle: Photograph of the modified
delivery catheter in the release position and corresponding high-
resolution CMR image. Right: Photograph and corresponding high-
resolution CMR image of the modified delivery catheter with the
loaded stent-valve, whose position within the delivery catheter can
be easily determined by its circumscribed susceptibility artifacts.
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of the balloon catheter alone could be monitored arti-
fact-free with dark contrast of the balloon (Figure 5a).
However, the stent-valve mounted on the balloon
catheter also showed major susceptibility artifacts in the
real-time sequence, potentially hindering exact device
placement in vivo (Figure 6a).
Corresponding to the high-resolution CMR images,
the distal part of the original delivery catheter for the
Medtronic CoreValve® prosthesis could be well visua-
lized without artifacts, while the catheter shaft exhibited
severe metal braiding artifacts. However, the distal part
could be monitored with good image quality during
slow manual release of the stent-valve, ensuring exact
CMR-guided placement and deployment of the prosthe-
sis (Figure 6b).
The modified, CMR-compatible delivery device could
be rendered completely free of any susceptibility arti-
facts during real-time imaging. The device constraints
were clearly visible to good advantage over the commer-
cially available device. In terms of precise deployment,
the modified device showed the same excellent behavior
as the commercial device, providing detailed display of
the deployment process with sufficiently high temporal
resolution (Figure 6c).
Flow Measurements
The flow pump delivered a defined pulsatile waveform
with a peak flow rate of 35 ml/s and a peak reverse flow
rate of 15 ml/s to simulate transaortic blood flow with
ECG triggering for evaluation of flow measurements. Flow
dynamics could be representatively assessed both qualita-
tively and quantitatively for both valves. Assessment of
flow could be displayed and measured with ECG-gated
cine PC sequences, acquiring 20 phases within the trigger
interval. By manually drawing regions of interest over the
appropriate flow areas (i.e. ventricular outflow and aortic
inflow), PC flow curves could be acquired with reliable
determination of flow direction and flow rate, revealing a
flow lobe with positive flow direction that was followed by
a weaker flow lobe with reversed flow direction. No funda-
mental differences were observed between the two pros-
theses. The reverse flow was sufficient to induce closure of
the valve leaflets for both valves, thereby revealing or
excluding potential aortic regurgitation (Figure 7).
Data Analysis
Results of the consensus grading of image quality
between radiologist and physicist are given in table 1. In
general, imaging of the devices under motion was asso-
ciated with less spatial image resolution and thus reduced
image quality compared to static high-resolution ima-
ging. However, this was not necessarily affecting overall
image quality grading (Table 1).
The Medtronic CoreValve® prosthesis in combination
with the modified delivery device provided excellent
visualization during longitudinal device movement and
during valve deployment without disturbing artifacts,
thereby enabling precise positioning. While the com-
mercial delivery device for the Medtronic CoreValve®
prosthesis showed severe artifacts only at the catheter
shaft, the entire guiding catheter for the Edwards
Sapien™ stent-valve was depicted poorly with severe sus-
ceptibility artifacts.
The high-resolution T1-weighted 3D FLASH images
were used for evaluation of the individual amount of RF
shielding within the two stent-valves (Figure 3). For
both devices, there was moderate signal attenuation
within the lumen of both stent frames, thus precluding
direct visualization of the three tenuous leaflets of the
integrated pericardial tissue valves in both coronal and
axial slices. RF signal attenuation amounted to 59 ± 7%
within the balloon-expandable stent-valve and to 57 ±
9% within the self-expandable stent-valve (p = ns).
Discussion
The present in vitro study evaluated the CMR characteris-
tics of the two currently commercially available TAVI
devices, the Edwards SAPIEN™ and the Medtronic Core-
Valve® bioprosthesis, and of a custom-built delivery device
for the Medtronic CoreValve® prosthesis - modified
towards CMR safety - in dedicated phantom models as an
initial step toward clinical application of real-time CMR-
guided TAVI in vivo. Real-time CMR guidance may be
desirable for the rapidly emerging TAVI procedure, since
it potentially overcomes inherent shortcomings of X-ray
fluoroscopy and angiography, which are currently used for
imaging guidance. Complementary to mitigation of radia-
tion exposure and nephrotoxicity of contrast media, the
TAVI procedure would benefit from real-time CMR gui-
dance due to its inherent unsurpassed soft-tissue contrast
and its 2D and 3D imaging capabilities in any oblique
orientation during navigation of the large-diameter cathe-
ters through the vasculature and, even more importantly,
during precise axial positioning of the stent-valve and
deployment. So far, only two provocative initial demon-
strations in the preclinical era of TAVI have addressed the
feasibility and potential value of combined device and tis-
sue imaging by CMR guidance in animal models using
entirely hand-made devices far from clinical approval and
applicability [23,24]. In contrast, CMR suitability of
approved and already commercially available TAVI
devices which might be readily transferred into CMR
application has not yet been evaluated.
However, collection of precise three dimensional infor-
mation about soft-tissue anatomy and precise visualization
of catheter instruments in relation to the surrounding
anatomy has proven to be difficult [3]. The optimal CMR
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characterized by a high spatial and temporal resolution
and, at the same time, a high contrast instrument signa-
ture in order to easily identify the instrument in the CMR
image [4]. A number of approaches have been developed
for depicting vascular instruments by CMR. Basically,
active and passive tracking is used to render catheters con-
spicuous on CMR. While passive catheters are conspicu-
ous based on their intrinsic material properties, active
catheters are conspicuous because they contain embedded
electronics that interact with the CMR system, usually
small RF receiver coils or antennas incorporated into the
tip or distal end of a catheter device that are connected to
the receiver ports of the CMR scanner with miniaturized
coaxial cables running through the catheter body. How-
ever, due to RF energy coupling with the RF transmitter
coil, these longitudinal cables might be a source of RF-
induced heating, thus rendering active catheter tracking
potentially hazardous for the patient [4]. In contrast, pas-
sive device tracking by CMR uses material-induced sus-
ceptibility artifacts of the interventional instrument for
visualization. Passive tracking often requires no hardware
or instrument modifications and, thus, appears to be parti-
cular promising in terms of potential clinical applications.
TAVI appears particularly attractive for a passive
CMR-guided approach, since device delivery here is per-
formed through large-diameter vessels and the delivery
Figure 6 Real-Time CMR. a. In vitro deployment of the Edwards
SAPIENTM stent-valve crimped onto the balloon catheter: The stent-
valve was advanced towards the proximal opening of a plastic tube
simulating the aortic annulus (first image). Targeting this “annulus”
the valve was positioned (second image) prior deployment by rapid
balloon inflation (third image) and deflation. Subsequently, the
balloon catheter was pulled back and correct valve position
evaluated (fourth image). rt-TrueFISP imaging provided poor
visualization with substantial image distortion due to severe
ferromagnetic valve artifacts, significantly impairing precise device
movement. b. Deployment of the Medtronic CoreValve® prosthesis
using the commercially available delivery catheter: The loaded stent-
valve was advanced (first image) until the delivery catheter tip was
positioned above the “annulus” (second image) before continuously
releasing the prosthesis. After expansion of the inflow-part at the
targeted position (third image), the valve was fully released and the
delivery catheter pulled back, now showing the unsheathed
proximal capsule (fourth image). rt-TrueFISP imaging displayed poor
visualization of the delivery catheter shaft showing severe
ferromagnetic artifacts. In contrast, the distal part covering the
crimped stent-valve could be better visualized with less image
distortion providing relatively smooth monitoring during stepwise
valve release. c. In vitro deployment of the Medtronic CoreValve®
prosthesis using the modified, CMR-compatible delivery catheter.
The loaded stent-valve was advanced (first image) until the delivery
catheter tip was positioned above the simulated annulus (second
image). After precise deployment of the inflow-part (third image),
the valve was fully released and the delivery catheter pulled back
(fourth image). rt-TrueFISP imaging provided excellent, artifact-free
device visualization allowing precise imaging guidance. The position
of the loaded stent-valve within the delivery device could be clearly
discerned by the circumscribed susceptibility artifacts of the
crimped nitinol stent, and the position of the retracting delivery
catheter sheath could also be clearly followed.
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between 18 and 24 French. Given these preconditions,
passive real-time visualization of the delivery device can
be performed without the need for additional device
modifications as needed for active visualization
approaches [3,4]. However, essential prerequisites for
performing TAVI procedures under CMR guidance are
CMR safety and CMR compatibility of the devices; these
considerations generally pose the major limitations to
clinical application of interventional CMR. CMR-safe
and -compatible devices are engineered to be conspicu-
ous, to preclude magnetic attraction and displacement,
to avoid distortion of the image and obscuration of the
relevant parts of the field of view as a result of large
magnetic susceptibility signal voids of incorporated
metal components, and to prevent RF related heating
during exposure to the high RF energy inherently
required to acquire the CMR images. Therefore, cathe-
ter delivery devices for use in CMR should not contain
any metal braidings or metal cores, neither ferromag-
netic, nor electrically conducting. Such metal cores or
braidings - which are often used in off-the-shelf cathe-
ters designed for fluoroscopically-guided procedures for
material reinforcement and to increase stiffness and tor-
queability - may potentially lead to magnetic attraction
forces and large ferromagnetic susceptibility artifacts
that exceed the dimension of the actual device by far,
thus disturbing CMR images to large extent. Beyond the
problem of potentially generating artifacts and disturb-
ing image quality, such longitudinal electrically conduct-
ing metal cores and braidings may act as antennas in
the CMR environment, locally increasing the radiofre-
quency (RF) Specific Absorption Rate (SAR) near such
metallic implants. The local electric field can be ampli-
fied, especially if the implants are composed of long
conducting structures that potentially can couple signifi-
cantly with the RF energy of the body coil. This might
lead to excessive local tissue heating if standing resonat-
ing waves are generated [25-27]. These resonance
effects, however, occur only when the length of wire-like
structures or longitudinal implants exceeds one half of
the RF wavelength, i.e. around 26 cm for 1.5 T in
human tissue [25]. For implants that are small compared
to the RF wavelength (e.g., stents, coils, endografts), RF
resonance is considered unlikely. Hence, both aortic
stent-valves used in this study showed no relevant RF
heating in non-clinical testing and have been approved
for CMR. According to the official instructions for use,
the Edwards Sapien bioprosthesis may be scanned safely
in a static magnetic field of 3 Tesla or less, in a spatial
Figure 7 Flow measurements. Left: Flow phantom. The custom-built phantom model consists of an interconnected system of plastic tubes
contained within a water-filled bottle which is linked in a closed circuit to a CMR-compatible flow pump providing pulsatile flow. Middle:
Qualitative assessment of flow exemplified with the Medtronic CoreValve® prosthesis using flow-sensitive phase-contrast cine CMR. Right: Flow
curves integrated over time were obtained up and downstream of the stent-valve (arrows) using an ECG-triggered, velocity-encoded, through-
plane phase-contrast sequence demonstrating a competent valve without relevant regurgitation.
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mum whole-body-averaged specific absorption rate of
3.0 W/kg for 15 minutes of scanning. The device pro-
duces a maximum temperature increase of 0.5°C at a
maximum whole-body-averaged specific absorption rate
of 3.0 W/kg for 15 minutes of MRI. Similarly, the Med-
tronic CoreValve® bioprosthesis may be scanned safely
in a static magnetic field of 3 Tesla or less, in a spatial
gradient field of 1500 Gauss/cm or less and with a max-
imum whole-body-averaged specific absorption rate of
2.0 W/kg for 15 minutes of scanning, according to the
official instructions for use. During testing the device
has been shown to produce a maximum temperature
increase of 3.5°C at 64 MHz and 3.6°C at 128 MHz for
a whole-body-averaged specific absorption rate of 2 W/
kg for 15 minutes of MRI.
Our study showed that the delivery device of the
Edwards SAPIEN™ stent-valve revealed major suscept-
ibility artifacts caused by considerable ferromagnetic
metal braiding, thus also raising concerns regarding
RF-related device heating. Additionally, significant ferro-
magnetic attraction forces were observed, which poten-
tially may impose a risk of uncontrollable migration
during CMR-guided TAVI, thereby precluding in vivo
application. The stainless steel-based prosthesis itself
was not subject to ferromagnetic attraction, but pro-
duced susceptibility artifacts exceeding the valve’s
dimensions; this might hinder exact placement in vivo.
In contrast, the nitinol-based self-expandable Medtronic
CoreValve® bioprosthesis was excellently visualized, with
delineation of even small device details. While the com-
mercial delivery catheter shaft revealed strong ferromag-
netic artifacts due to metal braiding similar to those
seen in the device for the Edwards SAPIEN™ valve, the
distal part containing the mounted stent-valve could be
visualized artifact-free and allowed for precise valve
positioning and deployment without image distortion at
the region of interest. Since engineering data and initial
screening of both commercially available delivery sys-
tems for metallic components revealed reinforcement of
both devices by metal braiding, design modifications of
the mechanically simple delivery device of the self-
expandable, nitinol-based Medtronic CoreValve®
b i o p r o s t h e s i st o w a r di m p r o v e dC M Rs a f e t ya n dC M R
compatibility were performed. The modified device was
designed completely without reinforcing the delivery
device shaft with metal braiding but with preservation
of rigidity and flexibility as the key mechanical device
properties for in vivo application. These modifications
toward enhancing CMR compatibility and CMR safety
Table 1 Consensus Grading of Image Quality
High-Resolution
T1-Weighted 3D FLASH Imaging
Real-Time
TrueFISP Imaging
1. Edwards SAPIEN™ Prosthesis and RetroFlex Delivery Device
- Visualization of the prosthesis 2 1
- Visualization of the delivery device 1 1
- Visualization of the balloon catheter 3 3
- Monitoring of delivery device movement NA 1
- Monitoring of balloon catheter movement and balloon-inflation NA 3
- Monitoring of delivery device movement with crimped stent-valve NA 1
- Monitoring of valve deployment NA 1
- Visualization of deployed prosthesis 2 1
2. Medtronic CoreValve® and Dedicated Delivery Devive
- Visualization of the prosthesis 3 3
- Visualization of the delivery device 1 (shaft), 3 (distal part) 1 (shaft), 3 (distal part)
- Monitoring of delivery device movement NA 1 (shaft), 3 (distal part)
- Monitoring of delivery device movement with loaded stent-valve NA 1 (shaft), 3 (distal part)
- Monitoring of valve deployment NA 1 (shaft), 3 (distal part)
- Visualization of deployed prosthesis 3 3
3. Medtronic CoreValve® and Modified, CMR-Compatible Delivery Device
- Visualization of the prosthesis 3 3
- Visualization of the delivery device 3 3
- Monitoring of delivery device movement NA 3
- Monitoring of delivery device movement with loaded stent-valve NA 3
- Monitoring of valve deployment NA 3
- Visualization of deployed prosthesis 3 3
NA: not applicable.
1: severe artifacts with poor visualization; 2: minor artifacts allowing fair visualization; 3: excellent visualization with delineation of device details.
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real-time visualization of catheter movement and valve
deployment using rt-TrueFISP imaging. Therefore, the
Medtronic CoreValve® prosthesis may be suited for real-
time CMR-based procedural guidance after effective
design modifications.
To achieve high instrument to background contrast in
the dynamic phantom experiments, a fast rt-TrueFISP
sequence was used for data acquisition [28]. Such
sequences, when used with high excitation flip angles,
provide high blood signal even without administration
of a contrast agent. rt-TrueFISP imaging with Cartesian
k-space filling provided a frame rate of 2.5 images per
second and proved sufficient for direct and precise con-
trol of catheter movement and stepwise valve deploy-
ment. No detectable image reconstruction delay and no
disturbing movement artifacts were observed.
Finally, with respect to CMR surveillance after valve
implantation, our study could demonstrate in phantom
experiments that dynamic flow assessment of the
implanted aortic stent-valves can be performed non-
invasively using flow-sensitive PC imaging, which is
already used for flow measurements in the clinical eva-
luation of valvular heart disease [29,30]. Using flow-sen-
sitive PC imaging, aortic regurgitation after valve
implantation can be rapidly detected, which is important
in clinical practice since hemodynamical relevant aortic
regurgitation after TAVI is associated with an increased
in-hospital mortality and may require immediate post-
dilation of the prosthesis using a balloon [31].
When moving towards preclinical application in ani-
mal experiments, the other steps of the TAVI procedure
besides valve implantation need to be also taken into
consideration, specifically passage of the stenotic aortic
valve and its preparation by prior balloon aortic valvulo-
plasty. While our experiments showed, that the Nu-Med
Z-Med II balloon-catheter is suitable for real-time
CMR-guidance and may thus be used for balloon valvu-
loplasty, CMR-compatible guidewires need to be consid-
ered for passage of the aortic valve and for propagation
of the delivery catheters. According to the literature,
there are currently two groups that work towards devel-
opment and commercialization of first CMR-compatible
guidewires [8,9,32-34]. Such CMR-compatible guide-
wires are polyetheretherketone-based or built from
fiberglass or other non-metallic, reinforced components
and are passively visualized by their susceptibility arti-
facts. Whether mechanical stability and other properties
will be equivalent to the commercially used products or
at least be practical in an in vivo situation remains to be
tested in according animal experiments which we are
planning to conduct in a swine model.
As a future perspective, it also needs to be evaluated
whether preinterventional evaluation for and procedural
guidance during TAVI can be performed exclusively
under CMR imaging. The TAVI procedure requires
thorough preinterventional screening regarding suitabil-
ity of the peripheral access vessels, the required valve
size and potential shift of calcified plaques towards the
coronary ostia. At present, this issue is addressed by
multimodality imaging using computed tomography,
invasive angiography and transesophageal echocardio-
graphy. Whether CMR is suited to obviate the need for
multimodality imaging is currently unclear and needs to
be further evaluated, especially since calcifications can
currently not directly be assessed well by CMR.
Limitations of the Study
Naturally, our in vitro study has some limitations that
need to be acknowledged. First, we used a rather simple
straight-tube phantom model for device propagation
and valve implantation not exactly resembling the more
tortuous in vivo geometry which may result in device
bending and a device orientation not parallel to the
main magnetic field axis. The need for device bending
raises concerns about the mechanical properties of the
modified delivery catheter for the Medtronic CoreValve®
prosthesis. In this study no additional bench-testing was
performed for the modified device but it could be
demonstrated that flexibility and rigidity was similar to
the original, reinforced device by simple manual bend-
ing. The fact, that device orientation in vivo may not be
parallel to the main magnetic field axis has some poten-
tial relevance regarding image quality and RF shielding
measurements. Though our measurements give a clear
impression of device visualization and the amount of RF
shielding in a controlled in vitro setup, this issue needs
to be further addressed in the following animal experi-
ments. Second, we did not perform any RF heating mea-
surements for the commercial delivery devices.
However, since ferromagnetic attraction forces as well
as degraded imaging quality already precluded in vivo
application we did not deem those measurements neces-
sary. For the modified delivery catheter for the Medtro-
nic CoreValve® prosthesis RF heating measurements
were also not deemed necessary due to its construction
without any metallic components. Third, it needs to be
mentioned that meanwhile a new generation of the bal-
loon-expandable Edwards valve, the Edwards SAPIEN™
XT prosthesis, has entered the clinical arena. This latest
device iteration features a cobalt-chromium instead of
stainless steel stent frame, which may be better CMR-
compatible. Unfortunately, this new device was not
available to us at the time of the experiments. However,
this may not be surprising due to the expeditious evolu-
tion of this novel technology. Nevertheless, since the
delivery catheter is the main limitation precluding
CMR-guided TAVI, the conclusions of the present study
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metal components are involved in the complex mechan-
ism of the NovaFlex delivery catheter which not only
offers steerable deflection but also allows the valve to be
loaded onto the balloon catheter within the aorta
instead of outside the human body.
Conclusions
The present in vitro study demonstrates that the com-
mercially available nitinol-based, self-expandable Med-
tronic CoreValve® bioprosthesis is potentially suited for
real-time CMR-guided placement using passive device
visualization and rt-TrueFISP imaging after effective
design modifications of the delivery device. These obser-
vations provide a starting point for pursuing real-time
CMR-guided TAVI in vivo.
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